Typically, making a drug begins with identifying a protein associated with human disease. These proteins are known as “targets.” When it is confirmed that a target plays a role in a disease, an experiment known as a high-throughput screen is conducted to find a chemical compound or antibody that binds or “hits” the target in a way that alters the disease. Once chemical compounds or antibodies are identified by their binding to a target, these hits are enhanced to improve their safety and effectiveness. The resulting chemical compound or antibody becomes a drug candidate.
Novartis Oncology has a broad, deep pipeline that encompasses a spectrum of therapeutic approaches. Learn about our key therapeutic targets:
We are also exploring the next generation of immuno-oncology agents that have the promise of helping more patients and less mechanisms of resistance, as well as various combination strategies leveraging our broad targeted therapy portfolio with immuno-oncology agents.